Comparative Pharmacology
Head-to-head clinical analysis: FARESTON versus SOLTAMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FARESTON versus SOLTAMOX.
FARESTON vs SOLTAMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, exerting antiestrogenic effects in breast tissue.
Selective estrogen receptor modulator (SERM). Binds to estrogen receptors, competitively inhibiting estrogen binding. In breast tissue, acts as an antagonist; in bone and cardiovascular system, acts as an agonist.
60 mg orally once daily.
300 mg orally once daily for 5 days, starting on day 1 of menses.
None Documented
None Documented
The terminal elimination half-life of toremifene is approximately 5 days (range 2-10 days). The half-life of its main metabolite, N-desmethyltoremifene, is about 11 days. This long half-life supports once-daily dosing.
24-36 hours in adults; prolonged in renal impairment (up to 96 hours in ESRD). Steady-state reached in ~5 days.
FARESTON (toremifene) is extensively metabolized in the liver. Excretion is primarily fecal (approximately 70%) with renal excretion accounting for less than 10% of the dose as unchanged drug and metabolites.
Primarily renal (80-90% as unchanged drug); biliary/fecal excretion accounts for 10-20%.
Category C
Category C
Selective Estrogen Receptor Modulator
Selective Estrogen Receptor Modulator